Lyell Immunopharma (LYEL) Total Current Liabilities (2020 - 2026)

Lyell Immunopharma's Total Current Liabilities history runs 7 years deep, the most recent figure standing at $36.9 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 10.51% year-over-year to $36.9 million; the TTM figure through Mar 2026 stood at $36.9 million (down 10.51% YoY), while the FY2025 annual figure was $49.4 million, down 8.14% from the prior year.
• Total Current Liabilities came in at $36.9 million for Q1 2026 at Lyell Immunopharma, down from $49.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $53.8 million in Q4 2024 to a low of $30.8 million in Q1 2023.
• A 5-year average of $38.9 million and a median of $36.9 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 31.62% in 2023 and surged 55.82% in 2024, its largest moves.
• Lyell Immunopharma's Total Current Liabilities stood at $37.0 million in 2022, then declined by 6.78% to $34.5 million in 2023, then surged by 55.82% to $53.8 million in 2024, then fell by 8.14% to $49.4 million in 2025, then decreased by 25.23% to $36.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $36.9 million, $49.4 million, and $31.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison